Bishal Gyawali, Associate Professor at Queen’s University, shared a post on LinkedIn:
“New article alert! Just published in Journal of Clinical Oncology.
In this piece we question whether subcutaneous formulation of pembrolizumab adds any value to patients and health systems?
People argue subQ pembro is more convenient but a) is it really? And b) even if it is, what is the cost of that convenience?
In our opinion, this is simply a case of patent hopping which is expensive to health systems and thwarts efforts at dose optimization of immunotherapies.
Builds on a previous paper we published on cost of convenience in cancer care.”
Title: Beyond Convenience: Does Subcutaneous Pembrolizumab Add Value for Patients and Health Systems?
Authors: Laure-Anne Teuwen, Rachel P. Riechelmann, Bishal Gyawali
Read the Full Article.
Other articles featuring Bishal Gyawali on OncoDaily.
